14 completed, 2 unknown, 1 active not recruiting, 1 terminated. 19 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 14, Unknown 2, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow Meibomian Gland Dysfunction: new trials by email Literature Review of Meibomian Gland Dysfunction trials Research Report on Meibomian Gland Dysfunction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous Serum Obtained by a Closed-Circuit Collection Device Autologous Serum 20% - GVHD, Meibomian Gland Dysfunction (Disorder) | Phase 2 | Active not recruiting | GIANCARLO FATOBENE | 16 | 2025-06-20 | 2026-10-21 |
| Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex Vehicle of TP-03 - Meibomian Gland Dysfunction, Demodex Infestation of Eyelid | Phase 2 | Unknown | Tarsus Pharmaceuticals, Inc. | 36 | 2023-08-01 | 2024-04-09 |
| Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD TP-03, TP-03 Vehicle - Meibomian Gland Dysfunction, Blepharitis | Phase 2 | Completed | Tarsus Pharmaceuticals, Inc. | 39 | 2022-08-03 | 2025-10-01 |
| The Efficacy and Safety of Topical Vitamin D Drop on Meibomian Gland Function in Patients With Meibomian Gland Dysfunction Topical Vitamin D eye drop, Topical placebo eye drop - Meibomian Gland Dysfunction | Phase 2 / Phase 3 | Unknown | Shahid Beheshti University of Medical Sciences | 56 | 2022-07-25 | 2022-08-10 |
| Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction CBT-008 - Meibomian Gland Dysfunction | Phase 2 | Completed | Cloudbreak Therapeutics, LLC | 95 | 2022-03-04 | 2024-04-24 |
| Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction CBT-006 - Meibomian Gland Dysfunction | Phase 2 | Completed | Cloudbreak Therapeutics, LLC | 92 | 2021-09-05 | 2024-04-24 |
| Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD) AZR-MD-001 Active, AZR-MD-001 Vehicle - Meibomian Gland Dysfunction | Phase 2 | Completed | Azura Ophthalmics | 31 | 2020-07-17 | 2022-05-16 |
| Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD) AZR-MD-001 ointment/semi-solid drug - Meibomian Gland Dysfunction | Phase 2 / Phase 3 | Completed | Azura Ophthalmics | 32 | 2020-07-14 | 2023-01-25 |
| Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction AXR-270 Low Dose, AXR-270 High Dose, AXR-270 Vehicle - Posterior Blepharitis, Meibomian Gland Dysfunction | Phase 2 | Completed | AxeroVision, Inc. | 129 | 2020-06-16 | 2023-07-21 |
| An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD) AZR-MD-001 Vehicle, AZR-MD-001 Active Dose - Meibomian Gland Dysfunction (MGD), Contact Lens Discomfort (CLD) | Phase 2 | Completed | Azura Ophthalmics | 26 | 2019-10-04 | 2023-01-25 |
| Study to Evaluate the Safety and Efficacy of Minocycline Ointment in Subjects With Inflamed Meibomian Gland Dysfunction 0.3% Topical Minocycline Ointment, 1% Topical Minocycline Ointment, Topical Vehicle Ointment - Meibomian Gland Dysfunction, MGD-Meibomian Gland Dysfunction | Phase 2 | Completed | Hovione Scientia Limited | 270 | 2019-04-02 | 2021-03-05 |
| A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED) AZR-MD-001 Low Dose, AZR-MD-001 Mid Dose, AZR-MD-001 High Dose - Meibomian Gland Dysfunction, Dry Eye | Phase 2 | Completed | Azura Ophthalmics | 321 | 2018-09-10 | 2024-02-28 |
| Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD) Brimonidine 0.15%, Brimonidine 0.075%, Placebo - Dry Eye, Ocular Graft vs Host Disease | Phase 1 / Phase 2 | Terminated | Sandeep Jain, MD | 15 | 2016-05-01 | 2019-11-08 |
| Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease KPI-121, Vehicle - Blepharitis | Phase 2 | Completed | Kala Pharmaceuticals, Inc. | 206 | 2014-07-01 | 2021-01-11 |
| Study to Determine the Effect of Azasite on Corneal Surface Irregularity Azasite - Meibomian Gland Dysfunction | Phase 2 | Withdrawn | Philadelphia Eye Associates | 2013-03-01 | 2016-09-28 | |
| Oral Azithromycin Versus Doxycycline in Posterior Blepharitis Azithromycin, Doxycycline - Posterior Blepharitis | Phase 2 | Completed | Tehran University of Medical Sciences | 100 | 2013-01-01 | 2014-02-12 |
| A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction AGN-195263 0.1%, AGN-195263 0.03%, AGN-195263 0.01% - Meibomian Gland Dysfunction | Phase 2 | Completed | Allergan | 232 | 2012-08-22 | 2017-09-08 |
| Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction testosterone ophthalmic solution, vehicle of testosterone ophthalmic solution - Meibomian Gland Dysfunction | Phase 2 | Completed | ORA, Inc. | 60 | 2008-07-01 | 2020-10-22 |
| Topical IL-1-Ra for Treatment of Posterior Blepharitis 2.5% IL-1Ra, Placebo, 5% IL-1Ra - Posterior Blepharitis | Phase 1 / Phase 2 | Completed | Reza Dana, MD | 75 | 2008-01-01 | 2018-01-19 |
Blepharitis (3) · Dry Eye Syndromes (3) · Graft vs Host Disease (1) · Pain (1) · Stevens-Johnson Syndrome (1) · cyclopia sequence (1)
Eye Diseases (19) · Eyelid Diseases (19) · Lacrimal Apparatus Diseases (3) · Chemically-Induced Disorders (1) · Dermatitis (1) · Drug Eruptions (1) · Drug Hypersensitivity (1) · Drug-Related Side Effects and Adverse Reactions (1) · Erythema (1) · Erythema Multiforme (1) · Hypersensitivity (1) · Hypersensitivity, Delayed (1) · Immune System Diseases (1) · Mouth Diseases (1) · Neurologic Manifestations (1)
Azithromycin (2) · Lubricant Eye Drops (2) · Brimonidine Tartrate (1) · Doxycycline (1) · Interleukin 1 Receptor Antagonist Protein (1) · Loteprednol Etabonate (1)
Azura Ophthalmics (4) · Cloudbreak Therapeutics, LLC (2) · Tarsus Pharmaceuticals, Inc. (2) · Allergan (1) · AxeroVision, Inc. (1) · GIANCARLO FATOBENE (1) · Hovione Scientia Limited (1) · Kala Pharmaceuticals, Inc. (1) · ORA, Inc. (1) · Philadelphia Eye Associates (1) · Reza Dana, MD (1) · Sandeep Jain, MD (1) · Shahid Beheshti University of Medical Sciences (1) · Tehran University of Medical Sciences (1)
United States (11) · Australia (4) · Iran (2) · New Zealand (2) · Brazil (1) · Canada (1)
Bing Leng, MD (1) · Brad H Feldman, MD (1) · Damien Goldberg, MD (1) · George Magrath, MD (1) · H. Jerome Crampton, MD (1) · Houman D Hemmati, MD, PhD (1) · Jacqueline Tan-Showyin (1) · Jodi Luchs, MD (1) · John Sheppard, MD (1) · Joseph Tauber, MD (1) · Kelly Nichols, OD, PhD (1) · Kenneth Sall, MD (1) · Marc Abrams, MD (1) · Mitchell C Shultz, MD (1)